Abstract Klebsiella oxytoca is a gram-negative bacterium found in fecal microbiota and known to cause several infections in humans, including antibiotic-associated hemorrhagic colitis. We present here a case of colitis caused by K. oxytoca toxin-producing strains that evolved in chronic diarrhea successfully treated by fecal microbiota transplant.

More from our Archive

• DOI: 10.1093/cid/ciad428 2023

  Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

  Pranita D Tamma, Samuel L Aitken, Robert A Bonomo, Amy J Mathers, David van Duin, Cornelius J Clancy

• DOI: 10.1002/jmv.28950 2023

  Advances in HPV‐associated tumor management: Therapeutic strategies and emerging insights

  Xiangjin Gong, Hao Chi, Zhijia Xia, Guanhu Yang, Gang Tian

• DOI: 10.3390/vaccines11081304 2023

  Next-Generation TB Vaccines: Progress, Challenges, and Prospects

  Li Zhuang, Zhaoyang Ye, Linsheng Li, Ling Yang, Wenping Gong

• DOI: 10.3390/vaccines11081298 2023

  Pustular Eruption following COVID-19 Vaccination: A Narrative Case-Based Review

  Emmanouil Karampinis, Agoritsa Gravani, Polyxeni Gidarokosta, Dimitrios Petros Bogdanos, Angeliki-Viktoria Roussaki-Schulze, Efterpi Zafiriou

• DOI: 10.3390/v15081622 2023

  Lumpy Skin Disease: A Systematic Review of Mode of Transmission, Risk of Emergence and Risk Entry Pathway

  Juana Bianchini, Xavier Simons, Marie-France Humblet, Claude Saegerman

• DOI: 10.1002/jmv.29001 2023

  COVID‐19‐induced autoimmune thyroiditis: Exploring molecular mechanisms

  Bita Mohammadi, Kamal Dua, Mohammadreza Saghafi, Sachin Kumar Singh, Zahra Heydarifard, Milad Zandi

• DOI: 10.1093/infdis/jiad293 2023

  Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients

  Sunwen Chou, Sophie Alain, Carlos Cervera, Roy F Chemaly, Camille N Kotton, Jens Lundgren, Genovefa A Papanicolaou, Marcus R Pereira, Jingyang J Wu, Rose Ann Murray, Neil E Buss, Martha Fournier

• DOI: 10.1111/jdv.19380 2023

  Atopic dermatitis and risk of 14 site‐specific cancers: A Mendelian randomization study

  Qiang Liu, Li Chen, Yipeng Wang, Xiangyu Wang, Sarah J. Lewis, Jing Wang

• DOI: 10.1093/ofid/ofad383 2023

  Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent <i>Clostridioides difficile</i> Infection: Results From the PUNCH CD3 Clinical Trial

  Kevin W Garey, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Hongjue Wang, Glenn S Tillotson, Lindy L Bancke, Paul Feuerstadt

• DOI: 10.1093/cid/ciad409 2023

  Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial

  Yanfen Guan, Amy Puenpatom, Matthew G Johnson, Ying Zhang, Yujie Zhao, Joseph Surber, Aaron Weinberg, Carlos Brotons, Roman Kozlov, Rudy Lopez, Kathleen Coetzee, Joel Santiaguel, Jiejun Du, Angela Williams-Diaz, Michelle Brown, Amanda Paschke, Carisa De Anda, Josephine M Norquist